Ted Xiao

Dr. Tengfei Ted Xiao is a Co-Founder and the Chief Technology Officer of GV20 Therapeutics. Ted founded GV20 Therapeutics in 2016, after he finished his postdoctoral research training in Myles Brown lab at Dana-Farber Cancer Institute (DFCI). He was a pioneer of building up a functional CRISPR screening platform at DFCI. His expertise includes cancer genomics, high throughput screening techniques and bioinformatics. In GV20, he leads teams to build an AI-based antibody screening platform and has discovered several novel targets for cancer immunotherapy.